2017 Full year and fourth quarter
We announced our full year and fourth quarter 2017 results on Wednesday 7 February.
2011 Third Quarter - released 26 October 2011
Simon Dingemans, CFO, discusses our third quarter results 2011.
- Underlying sales growth of 6% and reported sales growth of 3%
- EPS before major restructuring 28.5p, dividend 17p (up 6%)
- Strong contribution from Japan: sales +57%
2011 Second Quarter - released 26 July 2011
Andrew Witty, CEO, and Simon Dingemans, CFO, discuss our second quarter results 2011.
- Q2 reported sales -2%
- EPS before major restructuring* 25p
- Underlying sales growth of 5%
- Increased pipeline visibility and dividend of 16p, up 7%
2011 First Quarter - released 27 April 2011
Andrew Witty, CEO, discusses our first quarter results 2011.
- Reported sales -10%, underlying sales +4%
- EPS before major restructuring 32.2p (+9%), dividend 16p (+7%)
2010 Fourth Quarter - released 03 February 2011
Andrew Witty, CEO, discusses our fourth quarter results 2010.
Other key information
Speeches & presentations
Search through our archive of speeches and presentations from conferences and events
Keep up to date with our news and recent announcements
Corporate Executive Team
The Corporate Executive Team manages our activities, and each member is responsible for a specific part of the business
A snapshot of our medicines and vaccines currently in development across three stages: phase I, phase II and phase III